Skip to content

Pregnancy and Postpartum CGM in GDM

Pregnancy and Postpartum Continuous Glucose Monitoring in Gestational Diabetes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07174245
Enrollment
40
Registered
2025-09-15
Start date
2025-08-05
Completion date
2027-07-01
Last updated
2026-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes

Keywords

gestational diabetes, continuous glucose monitor, glucose sensor, oral glucose tolerance test

Brief summary

Gestational diabetes (GDM) is one of the most common complications of pregnancy, and up to one third of women with GDM will have abnormal blood sugars after their pregnancy. To screen for abnormal blood sugars, standard of care is a 4-12 week postpartum oral glucose tolerance test (OGTT). However only 17-60% of women actually have this test performed. This study is to assess continuous glucose monitor data from the third trimester and up to 14 days postpartum to find predictors of postpartum OGTT results.

Detailed description

Those with GDM in current pregnancy using a Dexcom Continuous Glucose Monitoring (CGM) are eligible for enrollment. Participants use their CGM as usual during pregnancy and wear one sensor postpartum. They have their standard of care OGTT performed at around 6 weeks. They then complete a remote questionnaire after OGTT.

Interventions

DEVICEcontinuous glucose monitor

All participants who wear CGM

Sponsors

Icahn School of Medicine at Mount Sinai
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of gestational diabetes during current pregnancy * age 18 or older * prescribed Dexcom G7

Exclusion criteria

* Pregestational diabetes * known skin adhesive allergy which inhibits ongoing use of CGM * chronic oral steroid use.

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of postpartum TIR <96%up to 12 weeks postpartumSensitivity of postpartum time in range (TIR) \<96% to predict dysglycemia on OGTT. Range 70-180 mg/dL. Sensitivity determined by true positives of TIR \<96% and abnormal OGTT and false negatives would be TIR \<96% with normal OGTT.

Secondary

MeasureTime frameDescription
Specificity of postpartum TIR <96%up to 12 weeks postpartumSpecificity of postpartum TIR \<96% to predict dysglycemia on OGTT Specificity calculated by true negatives are TIR not \<96% and normal OGTT and false positive are TIR \<96% but normal OGTT results.
Experience survey questionnaireup to 12 weeks postpartum6 items in non validated questionnaire to be administered remotely. first 5 questions rated on a 5 point likert scale. question 6 asks participant to choose preference between glucose sensor or oral glucose tolerance test. Each question evaluated on its own scored 1 (Strongly disagree) to 5 (Strongly Agree). The questions are not summed.

Countries

United States

Contacts

CONTACTSarah Rancic
sarah.rancic@mssm.edu212-241-5355
CONTACTGrenye O'Malley
grenye.o'malley@mssm.edu212-241-7173
PRINCIPAL_INVESTIGATORGrenye O'Malley, MD

Icahn School of Medicine at Mount Sinai

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 9, 2026